The U.S. Food and Drug Administration has approved an expanded label for IZERVAY™ (avacincaptad pegol intravitreal solution) to provide greater flexibility in long-term disease management for physicians and patients. This approval follows Astellas' resubmission of a supplemental New Drug Application and is based on the positive results of the GATHER2 phase III clinical trial, which demonstrated significant slowing of geographic atrophy lesion growth over 2 years with well-tolerated treatment benefits observed as early as 6 months.

Source: Astellas